Highlight
Recent research validates the Anti-BNLF2b (P85-Ab) antibody as a highly sensitive and specific biomarker for early detection of nasopharyngeal carcinoma (NPC). The novel P85-Ab assay outperforms the traditional Epstein-Barr virus IgA antibody score and exhibits comparable performance to circulating EBV DNA testing. Its robust accuracy across demographic subgroups supports its potential for broad population-based NPC screening.
Study Background
Nasopharyngeal carcinoma (NPC) is a malignancy arising from the epithelial lining of the nasopharynx, with a high prevalence in Southeast Asia, particularly Taiwan. Early diagnosis is crucial for improving treatment outcomes and survival. Epstein-Barr virus (EBV) infection plays a central etiologic role in NPC pathogenesis, and EBV-related biomarkers have been instrumental in detection efforts. Presently, EBV IgA antibodies targeting viral capsid antigen (VCA) and nuclear antigen 1 (EBNA1), as well as circulating EBV DNA, are employed as screening tools but have limitations in sensitivity, specificity, or practicality for mass screening. Therefore, identifying novel, reliable biomarkers that can improve early NPC detection remains an unmet clinical need.
Study Design
This multicenter case-control study was conducted from July 2010 to December 2014 across six medical centers in northern and central Taiwan. The cohort included 892 patients with newly diagnosed NPC and 1804 control individuals without NPC. Archived blood samples collected at enrollment were analyzed for total antibodies to a putative EBV gene product encoded by BNLF2b (referred to as P85-Ab). Comparative analyses were performed against established EBV VCA-IgA/EBNA1-IgA antibody scores and a circulating EBV DNA detection algorithm. The primary endpoints were sensitivity and specificity for NPC detection, with subgroup analyses based on disease stage, demographics, family history, and lifestyle factors. Statistical analyses were completed between January 2025 and January 2026.
Key Findings
The P85-Ab test demonstrated high performance metrics for NPC detection. It achieved a sensitivity of 92.5% (95% CI, 90.7%-94.3%) and specificity of 98.7% (95% CI, 98.2%-99.2%), surpassing the EBV VCA-IgA/EBNA1-IgA antibody score whose sensitivity and specificity were 88.4% and 94.9%, respectively. The circulating EBV DNA algorithm showed sensitivity of 93.2% and specificity of 98.1%, comparable to P85-Ab. Notably, for early-stage NPC detection, P85-Ab sensitivity was 93%, outperforming 87% sensitivity for the other two assays.
Performance consistency was observed across sex, age, ethnicity, geographic region, NPC family history, and smoking status, indicating robustness of the P85-Ab biomarker. Estimates of the numbers needed to screen (NNS) at NPC incidence rates of 20 to 100 per 100,000 person-years were similar among the methods, ranging from approximately 1080 to 5650. Positive predictive values (PPVs) for P85-Ab were higher than for the EBV antibody score and circulating DNA testing, increasing from 1.4% to 6.6% when incidence rose from 20 to 100 per 100,000, indicating better clinical utility in high-risk populations.
Expert Commentary
This large-scale, independent validation of the P85-Ab test confirms prior evidence suggesting that this novel antibody is a sensitive and specific biomarker for NPC. Its superiority in early-stage detection is clinically significant because early NPC often presents asymptomatically or with nonspecific symptoms, complicating timely diagnosis. The stable performance across diverse demographic and risk subgroups strengthens the case for translational adoption in multiethnic populations.
Nonetheless, as a case-control design, the study may be prone to selection biases and spectrum bias. Prospective population-based cohort studies are warranted to confirm real-world screening efficacy, assess cost-effectiveness, and integrate P85-Ab testing into existing screening algorithms. Mechanistically, BNLF2b is a putative EBV gene product expressed during latent infection, making P85-Ab a biologically plausible target reflecting EBV-driven oncogenesis.
Conclusion
The novel Anti-BNLF2b antibody assay (P85-Ab) represents a promising advancement in NPC screening. Combining high sensitivity and specificity with consistent performance during early stages of disease, it stands as a practical biomarker for improving early NPC detection and potentially reducing morbidity and mortality in endemic regions. Further prospective validation and health economic analyses will be essential to establish guidelines for clinical implementation and public health screening programs.
Funding and Clinical Trials
This study was supported by collaborative multicenter research grants within Taiwan’s health institutes. Specific funders were not detailed in the abstract. No clinical trial registration number was provided.
References
- Hsu WL, Tang J, Lam HY, et al. Novel Anti-BNLF2b Antibody Screening and Early Detection of Nasopharyngeal Carcinoma. JAMA Otolaryngol Head Neck Surg. 2026;152(7):669-676. PMID: 42166171.
- Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999;59(6):1188-1191.
- Stevens SJ, Verkuijlen SA, Hariwiyanto B, et al. A new enzyme-linked immunosorbent assay to detect immunoglobulin A antibodies against Epstein-Barr virus in nasopharyngeal carcinoma diagnosis. J Clin Microbiol. 2004;42(1):146-151.
- Chan KCA, Woo JK, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med. 2017;377(6):512-522.